glp 1 pyy Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity Hormonal Gut–Brain Signaling for the

Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimers disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs use...

Treating type2 diabetes has shifted from a gluco-centric approach to broader cardio-renal-metabolic strategy, driven by the use of disease-modifying medications

Physiological Effects Semaglutide exerts its therapeutic benefits through multiple complementary mechanisms: Enhanced Insulin Secretion: Stimulates glucose-dependent insulin release from pancreatic beta cells, improving postprandial glucose control[3][4] Glucagon Suppression: Inhibits glucagon release, reducing hepatic glucose production and improving fasting blood glucose levels[3][4] Delayed Gastric Emptying: Slows the movement of food from the stomach to the small intestine, reducing postprandial glucose excursions and promoting satiety[4][5] Appetite Reduction: Directly affects the central nervous system to decrease food intake and energy consumption[4][5] Improved Metabolic Flexibility: Enhances the body's ability to switch between energy substrates based on availability[2] At the cellular level, semaglutide primarily operates through the AMPK (AMP-activated protein kinase) pathway, which regulates cellular energy homeostasis and improves insulin sensitivity

It depends on the patient, their body, and their long-term goals

Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable

RegenMD prescribes compounded GLP-1 therapy with personalized dosing tailored to your body and goals